The role of neurotransmitters and neurohormones in obsessive-compulsive disorder

International Review of Psychiatry

Volumn 9, Issue 1, 1997, Pages 31-44

  Greenberg, Benjamin D ^a   Altemus, Margaret ^a   Murphy, Dennis L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROHORMONE; NEUROTRANSMITTER; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR;

GONAD; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NEUROTRANSMISSION; OBSESSION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SYNAPSE;

EID: 0030939930     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540269775574     Document Type: Review

References (137)

1. ALTEMUS, M. (1995). Neuroendocrinology of obsessive-compulsive disorder. In Advances in biological psychiatry, Vol. 1 (pp. 215-233). JAI Press Inc.
2. ALTEMUS, M. & MURPHY, D. L. (1996). Animal models of obsessive-compulsive disorder. In H. G. M. WESTENBERG, D. L. MURPHY & J. A. DEN BOER (Eds), Advances in the neurobiology of anxiety disorders, (pp. 261-294). New York: John Wiley & Sons.
3. ALTEMUS, M., PIGOTT, T. A., KALOGERAS, K. T. DEMITRACK, M., DUBBERT, B., MURPHY, D. L. & GOLD, P. W. (1992). Abnormalities in the regulation of vasopression and corticotropin releasing factor secretion in obsessive-compulsive disorder. Archives of General Psychiatry, 49, 9-20.
4. ALTEMUS, M., PIGOTT, T., L'HEUREUX, F., DAVIS, C. L., RUBINOW, D. R., MURPHY D. L. & GOLD, P. W. (1993). CSF somatostatin in obsessive-compulsive disorder. American Journal of Psychiatry, 150, 460-464.
5. ALTEMUS, M., SWEDO, S. E., LEONARD, H. L., RICHTER, D., RUBINOW, D. R., POTTER, W. Z. & RAPOPORT, J. L. (1994). Changes in cerebrospinal fluid neurochemistry during treatment of obsessive-compulsive disorder with clomipramine. Archives of General Psychiatry, 51, 794-803.
6. ALTEMUS, M., MURPHY, D. L., GREENBERG, B. & LESCH, K. P. (1996). Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder. American Journal of Medical Genetics (Neuropsychiatric Genetics), 67, 409-411.
7. ALTEMUS, M., MICHELSON, D., GALLIVEN, E., GOLD, P. W. & MURPHY, D. L. (1996). Hypothalamic-pituitary-adrenal axis activity in obsessive-compulsive disorder. Psychoneuroendocrinology (in press).
8. BAILLY, D., SERVANT, D., DEWAILLY, D., BEUSCART, R., RACADOT, A., FOSSATI, P. & PARQUET, P. J. (1994). Corticotropin releasing factor stimulation test in obsessive compulsive disorder. Biological Psychiatry, 35, 143-146.
9. BAKER, R. W., CHENGAPPA, K. N. & BAIRD, J. W. (1992). Emergence of obsessive-compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry, 53, 439-442.
10. BARR, L. C., GOODMAN, W. K., PRICE, L. H., MCDOUGLE, C. J. & CHARNEY, D. S. (1992). The serotonin hypothesis of obsessive compulsive disorder: implications of pharmacologic challenge studies. Journal of Clinical Psychiatry, 54, 17-28.
11. BARR, L. C., GOODMAN, W. K. & PRICE, L. H. (1993). The serotonin hypothesis of obsessive compulsive disorder. International Clinical Psychopharmacology, 8, 79-82.
12. BARR, L. C., GOODMAN, W. K., MCDOUGLE, C. J., DELGADO, P. L., HENINGER, G. R., CHARNEY, D. S. & PRICE, L. H. (1994). Tryptophan depletion in patients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Archives of General Psychiatry, 51, 309-317.
13. BASTANI, B., ARORA, R. C. & MELTZER, H. Y. (1991). Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biological Psychiatry, 30, 131-139.
14. BAXTER, L. R. J. & BRODY, A. (1996). Neuroimaging in obsessive-compulsive disorder: advances in understanding neuroanatomy. In H. G. M. WESTENBERG, J. A. DEN BOER & D. L. MURPHY (Eds), Advances in the neurobiology of anxiety disorders (pp. 329-348). New York: John Wiley & Sons.
15. BAXTER, L. R., SCHWARTZ, J. M. & BERGMAN, K. S. (1992). Caudate glucose metabolic rate changes with drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry, 49, 681-689.
16. BEL, N. & ARTIGAS, F. (1993). Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse, 15, 243-245.
17. BENJAMIN, J., GREENBERG, B. & MURPHY, D. L. (1996). Daily administration of m-chlorophenylpiperazine to healthy human volunteers rapidly attenuates many of its behavioral, hormonal, cardiovascular and temperature effects. Psychopharmacology, 127, 140-149.
18. BENKELFAT, C., MURPHY, D. L., ZOHAR, J., HILL, J. L., GROVER, G. & INSEL, T. R. (1989). Clomipramine in obsessive-compulsive disorder: further evidence for a serotonergic mechanism of action. Archives of General Psychiatry, 46, 23-28.
19. BENKELFAT, C., GEORGE, D. T., MURPHY, D. L., HILL, J. L., NUTT, D. & LINNOILA, M. (1990a). Serotonin: from cell biology to pharmacology and therapeutics. In R. PAOLETTI & P. M. VANHOUTE (Eds) Serotonin: from cell biology to therapeutics. Boston: Kluwer Academic Publishers.
20. BENKELFAT, C., NORDAHL, T. E. & SEMPLE, W. E. (1990b). Local cerebral glucose metabolic rates in obsessive-compulsive disorder: patients treated with clomipramine. Archives of General Psychiatry, 47, 840-848.
21. BLIER, P. & BERGERON, R. (1995). Serotonergic augmentation strategies in drug-resistant obsessive compulsive disorder. San Juan, Puerto Rico: American College of Neuropsychopharmacology.
22. BLIER, P. & DE MONTIGNY, C. (1992). Lack of efficacy of lithium augmentation in obsessive-compulsive disorder: the perspective of different regional effects of lithium on serotonin release in the central nervous system. Journal of Clinical Psychopharmacology, 12, 65-66.
23. BLIER, P. B., DE MONTIGNY, C. & CHAPUT, Y. (1990). A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. Journal of Clinical Psychiatry, 51, 14-20.
24. 1A serotonin neuroreceptor and tryptophan oxygenase genes in a large British kindred multiply affected with Tourette's syndrome, chronic motor tics, and obsessive-compulsive behavior. American Journal of Psychiatry, 152, 437-440.
25. BROOCKS, A., PIGOTT, T. A., CANTER, S., GRADY, T. A., L'HEUREUX, F., HILL, J. L. & MURPHY, D. L. (1992). Acute administration of ondansetron and m-CPP in patients with obsessive-compulsive disorder (OCD) and controls: behavioral and biological results. Biological Psychiatry, 31, 174A.
26. 3 receptor antagonist, ondansetron, modifies the behavioral responses to intravenous m-chlorophenylpiperazine (m-CPP) in health volunteers. Psychopharmacology, in press.
27. BUTTOLPH, M. L. & HOLLAND, A. (1990). Obsessive compulsive disorder in pregnancy and childbirth. In M. JENIKE, L. BAER & W. E. MINICHIELLO (Eds), Obsessive-compulsive disorders, theory and management. Chicago: Yearbook Medical Publishers.
28. CASAS, M., ALVAREZ, E., DURO, P., GARCIA-RIBERA, C., UDINA, C., VELAT, A., ABELLA, D., RODRIGUEZ-ESPINOSA, J., SALVA, P. & JANE, F. (1986). Anti-androgenic treatment of obsessive-compulsive neurosis. Acta Psychiatrica Scandinavica, 73, 221-222.
29. CATALANO, M., SCIUTO, G., DI BELLA, D., NOVELLI, E., NOBILE, M. & BELLODI, L. (1994). Lack of association between obsessive-compulsive disorder and the dopamine D3 receptor gene: some preliminary considerations. American Journal of Medical Genetics, 54, 253-255.
30. CHARNEY, D. S., GOODMAN, W. K., PRICE, L. H., WOODS, S. W., RASMUSSEN, S. A. & HENINGER, G. R. (1988). Serotonin function in obsessive-compulsive disorder: a comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Archives of General Psychiatry, 45, 177-185.
31. CHOUINARD, G., BELANGER, M. C. & SULTAN, S. (1995). Potentiation of fluoxetine by aminoglutethimide steroid suppression in OCD: a case report. APA Annual Meeting, New Research Abstracts, p. 162.
32. CLOMIPRAMINE COLLABORATIVE STUDY GROUP (1991). Clomipramine in the treatment of patients with obsessive compulsive disorder. Archives of General Psychiatry, 46, 730-738.
33. COCCARO, E. F. & MURPHY, D. L. (1990). Serotonin in major psychiatric disorders. Washington DC: American Psychiatric Press.
34. COHEN, L. S. & ROSENBAUM, J. F. (1987). Clonazepam: new uses and potential problems. Journal of Clinical Psychiatry, 48, 50-55.
35. COTTRAUX, J., MOLLARD, E., BOUVARD, M., MARKS, I., SLUYS, M., NURY, A. M., DOUGE, R. & CIALDELLA, P. (1990). A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. International Clinical Psychopharmacology, 5, 17-30.
36. 1C receptors. Trends in Pharmacological Sciences, 11, 181-182.
37. DEBELLIS, M. D., GERACIOTI, T. D., ALTEMUS, M. & KLING, M. A. (1993a). Effects of fluoxetine treatment on CSF monoamine metabolites in patients with major depression. Biological Psychiatry, 33, 636-641.
38. DEBELLIS, M. D., GOLD, P. W., GERACIOTI, T. D., LISTWAK, S. J. & KLING, M. A. (1993b). Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopression in patients with major depression. American Journal of Psychiatry, 150, 656-657.
39. DELGADO, P. L., CHARNEY, D. S., PRICE, L. H., GOODMAN, W. K., AGHAJANIAN, G. K., LANDIS, H. & HENINGER, G. R. (1988). Behavioral effects of acute tryptophan depletion in depressed and obsessive compulsive disorder (OCD) patients. Abstracts Society of Neuroscience, 14, 970.
40. DELGADO, P. L., CHARNEY, D. S., PRICE, L. H., AGHAJANIAN, G. K., LANDIS, H. & HENINGER, G. R. (1990). Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Archives of General Psychiatry, 47, 411-418.
41. DEN BOER, J. A. & WESTENBERG, H. G. M. (1996). Involvement of serotonin receptor subtypes in panic disorder: a critical appraisal of the evidence. In H. G. M. WESTENBERG, D. L. MURPHY & J. A. DEN BOER (Eds), Advances in the neurobiology of anxiety disorders (pp. 139-173). New York: John Wiley & Sons.
42. DEVEAUGH-GEISS, J., MOROZ, G., BIEDERMAN, J., CANTWELL, D., FONTAINE, R., GREIST, J. H. & REICHLER, R. (1992). Clomipramine hydrochloride in childhood and adolescent obsessive compulsive disorder - a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 45-49.
43. EL MANSARI, M., BOUCHARD, C. & BUER, P. (1995). Alteration of serotonin release in the guinea pig orbital-frontal cortex by selective serotonin reuptake inhibitors: relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology, 13, 117-127.
44. 2 receptor and fluvoxamine effect in obsessive-compulsive disorder. Human Psychopharmacology, 7, 287-289.
45. FEDER, R. (1988). Lithium augmentation of clomipramine. Journal of Clinical Psychiatry, 49, 458.
46. FERNANDEZ, E. & LOPEZ-IBOR, J. (1967). Clomipramine in resistant psychiatric disorders and other treatments. Actas Luso Españolas Neurología Psiquiatría Ciencias Afines, 26, 119.
47. FINEBERG, N. A., BULLOCK, T., MONTGOMERY, D. B. & MONTGOMERY, S. A. (1992). Serotonin reuptake inhibitors are the treatment of choice in obsessive-compulsive disorder. International Clinical Psychopharmacology, 7(Suppl. 1), 43-47.
48. FREEMAN, M. F., TRIMBLE, M. R., DEAKIN, J. F., STOKES, T. M. & ASHFORD, J. J. (1994). Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry, 55, 301-305.
49. GEHRIS, T. L., KATHOL, R. G., BLACK, D. W. & NOYES, R. (1990). Urinary free cortisol levels in obsessive-compulsive disorder. Psychiatry Research, 32, 151-158.
50. GLENNON, R. A. & DUKAT, M. (1995). Serotonin receptor subtypes in psychopharmacology. In F. E. BLOOM & J. J. KUPFER (Eds), The fourth generation of progress. New York: Raven Press.
51. GOLDEN, R. N., MORRIS, J. E. & SACK, D. A. (1988). Combined lithium-tricyclic treatment of obsessive-compulsive disorder. Biological Psychiatry, 23, 181-185.
52. GOODMAN, W. K., PRICE, L. H., RASMUSSEN, S. A., DELGADO, P. L., HENINGER, G. R. & CHARNEY, D. S. (1989). Efficacy of fluvoxamine in obsessive compulsive disorder: a double blind comparison with placebo. Archives of General Psychiatry, 46, 36-44.
53. GOODMAN, W. K., MCDOUGLE, C. J., PRICE, L. H., RIDDLE, M. A., PAULS, D. L. & LECKMAN, J. F. (1990). Beyond the serotonin hypothesis: a role for dopamine in some forms of obsessive compulsive disorder? Journal of Clinical Psychiatry, 51(8 Suppl.), 36-43.
54. GOODMAN, W. K., MCDOUGLE, C. J., PRICE, L. H., BARR, L. C., HILLS, O. F., CAPLIK, J. F., CHARNEY, D. S. & HENINGER, G. R. (1995). m-chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biological Psychiatry, 38, 138-149.
55. GRADY, T., PIGOTT, T. A., L'HEUREUX, F., HILL, J. L., BERNSTEIN, S. E. & MURPHY, D. L. (1993). Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. American Journal of Psychiatry, 150, 819-821.
56. GREENBERG, B. D., BENJAMIN, J. & MURPHY, D. L. (1994). Biphasic effects of metergoline in fluoxetine-treated OCD patients. Biological Psychiatry, 35, 615.
57. GREIST, J. H. (1992). A multicentre, parallel design, double-blind, placebo-controlled trial. XVIIIth CINP Congress, Nice, France.
58. GREIST, J., CHOUINARD, G., DUBOFF, E., HALARIS, A., KIM, S. W., KORAN, L., LIEBOWITZ, M., LYDIARD, R. B., RASMUSSEN, S., WHITE, K. et al. (1995a). Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Archives of General Psychiatry, 52, 289-295.
59. GREIST, J. H., JEFFERSON, J. W., KOBAK, K. A., KATZELNICK, D. J. & SERLIN, R. C. (1995b). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Archives of General Psychiatry, 52, 53-60.
60. HANNA, G. L., YUWILER, A. & CANTWELL, D. P. (1991). Whole blood serotonin in juvenile obsessive-compulsive disorder. Biological Psychiatry, 29, 738-744.
61. HOLLANDER, E. (1995). Behavioral response to pharmacological challenges: potentials and pitfalls. Biological Psychiatry, 37, 831-833.
62. HOLLANDER, E., FAY, M., COHEN, B., CAMPEAS, R., GORMAN, J. M. & LIEBOWITZ, M. R. (1988). Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. American Journal of Psychiatry, 145, 1015-1017.
63. HOLLANDER, E., DECARIA, K. M., SCHNEIER, F. R., SCHNEIER, H. A., LIEBOWITZ, M. R. & KLEIN, D. F. (1990). Fenfluramine augmentation of serotonin reuptake blockade antiobsessional treatment. Journal of Clinical Psychiatry, 51, 119-122.
64. HOLLANDER, E., DECARIA, C., GULLY, R., NITESCU, A., SUCKOW, R. F., GORMAN, J. M., KLEIN, D. F. & LIEBOWITZ, M. R. (1991). Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder. Psychiatry Research, 36, 1-17.
65. HOLLANDER, E., DECARIA, C. M., NITESCU, A., GULLY, R., SUCKOW, R. F., COOPER, T. B., GORMAN, J. M., KLEIN, D. F. & LIEBOWITZ, M. R. (1992). Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry, 49, 21-28.
66. INSEL, T. R. (1992). Toward a neuroanatomy of obsessive-compulsive disorder. Archives of General Psychiatry, 49, 739-744.
67. INSEL, T. R., MUELLER, E. A., ALTERMAN, I., LINNOILA, M. & MURPHY, D. L. (1985). Obsessive-compulsive disorder and serotonin: Is there a connection? Biological Psychiatry, 20, 1174-1188.
68. JACOBSEN, F. M. (1995). Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Journal of Clinical Psychiatry, 56, 423-429.
69. JENIKE, M. A., BAER, L. & BUTTOLPH, L. (1991). Buspirone augmentation of fluoxetine in patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry, 52, 13-14.
70. KAHN, R. S. & WETZLER, S. (1991). m-chlorophenylpiperazine as a probe of serotonin function. Biological Psychiatry, 30, 1139-1166.
71. KATZ, R. J. & DEVEAUGH-GEISS, J. (1990). The antiobsessional effects of clomipramine do not require concomitant affective disorder. Psychiatry Research, 31, 121-129.
72. KETTER, T. A., GEORGE, M. S., KIMBRELL, T. A., BENSON, B. E. & POST, R. M. (1997). Functional brain imaging in mood and anxiety disorders. In A. J. RUSH (Ed.), Current review of mood disorders. Philadelphia: Current Medicine (in press).
73. KORAN, L. M., MCELROY, S. L. & DAVIDSON, J. R. T. (1995). Fluvoxamine versus clomipramine for OCD: a double-blind comparison. APA Annual Meeting, New Research Abstracts, p. 150.
74. KRUESI, M. J. P., SWEDO, S., LEONARD, H., RUBINOW, D. R. & RAPOPORT, J. L. (1990). CSF somatostatin in childhood psychiatric disorders: a preliminary investigation. Psychological Research, 33, 277-284.
75. 2 receptor binding and 5-HT transporter mRNA expression in rat brain. Brain Research, 648, 157-161.
76. LECKMAN, J. F., GOODMAN, W. K., NORTH, W. G., CHAPPELL, P. B., PRICE, L. H., PAULS D. L., ANDERSON, G. M., RIDDLE, M. A., MCSWIGGAN-HARDIN, M., MCDOUGLE, C. J., BARR, L. C. & COHEN, D. J. (1994). Elevated cerebrospinal fluid levels of oxytocin in obsessive-compulsive disorder. Comparison with Tourette's syndrome and healthy controls. Archives of General Psychiatry, 51, 782-792.
77. LECKMAN, J. F., GOODMAN, W. K., ANDERSON, G. M., RIDDLE, M. A., CHAPPELL, P. B., MCSWIGGAN-HARDIN, M. T., MCDOUGLE, C. J., SCAHILL, L. D., ORT, S. I., PAULS D. L. et al. (1995). Cerebrospinal fluid biogenic amines in obsessive compulsive disorder, Tourette's syndrome, and healthy controls. Neuropsychopharmacology, 12, 73-86.
78. LEONARD, H. L., SWEDO, S. E., RAPOPORT, J. L., KOBY, E., LENANE, M., CHESLOW, D. & HAMBURGER, S. (1989). Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Archives of General Psychiatry, 46, 1088-1092.
79. LEONARD, H. L., LENANE, M. C., SWEDO, S. E., RETTEW, D. C., GERSHON, E. S. & RAPOPORT, J. L. (1992). Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. American Journal of Psychiatry, 149, 1244-1251.
80. LESCH, K. P., AULAKH, C. S., WOLOZIN, B. L., TOLLIVER, T. J., HILL, J. L. & MURPHY, D. L. (1993). Regional brain expression of serotonin transporter mRNA and its regulation by reuptake inhibiting antidepressants. Molecular Brain Research, 17, 31-35.
81. LEVINE, J. & BELMAKER, R. H. (1996). Double-blind, placebo-controlled crossover trial of inositol for obsessive-compulsive disorder. American Journal of Psychiatry, 153, 1219-1221.
82. LIMA, L. (1991). Region-selective reduction of brain serotonin turnover rate and serotonin agonist-induced behavior in mice treated with clonazepam. Pharmacology, Biochemistry and Behavior, 39, 671-676.
83. LIMA, L., SALAZAR, M. & TREJO, E. (1993). Modulation of 5-HT1A receptors in the hippocampus and the raphe area of rats treated with clonazepam. Progress in Neuropsychopharmacology and Behavioral Biology, 17, 663-677.
84. MARKOVITZ, P. J., STAGNO, S. J. & CALABRESE, J. R. (1990). Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. American Journal of Psychiatry, 147, 798-800.
85. MCDOUGLE, C. J., GOODMAN, W. K., PRICE, L. H., DELGADO, P. L., KRYSTAL, J. H., CHARNEY, D. S. & HENINGER, G. R. (1990). Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal of Psychiatry, 147, 652-654.
86. MCDOUGLE, C. J., PRICE, L. H., GOODMAN, W. K., CHARNEY, D. S. & HENINGER, G. R. (1991). A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy. Journal of Clinical Psychopharmacology, 11, 175-184.
87. MCDOUGLE, C. J., GOODMAN, W. K., LECKMAN, J. F., LEE, N. C., HENINGER, G. R. & PRICE, L. H. (1994a). Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder: a double-blind, placebo-controlled study in patients with and without tics. Archives of General Psychiatry, 51, 302-308.
88. MCDOUGLE, C. J., GOODMAN, W. K., & PRICE, L. H. (1994b). Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. Journal of Clinical Psychiatry, 55(Suppl. 3), 24-31.
89. MCDOUGLE, C. J., BARR, L. C., GOODMAN, W. K., PELTON, G. H., ARONSON, S. C., ANAND, A. & PRICE, L. H. (1995). Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. American Journal of Psychiatry, 152, 1812-1814.
90. MCTAVISH, D. & BENFIELD, P. (1990). Clomipramine: an overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs, 39, 136-153.
91. MONTELEONE, P., CATAPANO, F., BUONO, G. D. & MAJ, M. (1994). Circadian rhythms of melatonin, cortisol and prolactin in patients with obsessive-compulsive disorder. Acta Psychiatrica Scandinavica, 89, 411-415.
92. MONTGOMERY, S. A. & MANCEAUX, A. (1992). Fluvoxamine in the treatment of obsessive compulsive disorder. International Clinical Psychopharmacology, 7(Suppl. 1), 5-9.
93. MONTGOMERY, S. A., MCINTYRE, A., OSTERHEIDER, M., SARTESCHI, P., ZITTERL, W., ZOHAR, J., BIRKETT, M., WOOD, A. J. & GROUP, T. L. E. O. S. (1993). A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. European Neuropsychopharmacology, 3, 143-152.
94. MORET, C. & BRILEY, M. (1990). Serotonin autoreceptor subsensitivity and antidepressant activity. European Journal of Phamacology, 180, 351-356.
95. MUELLER, E. A., MURPHY, D. L., SUNDERLAND, T. & JONES, J. (1985). A new postsynaptic serotonin receptor agonist suitable for studies in humans. Psychopharmacology Bulletin, 21, 701-704.
96. MURPHY, D. L. (1991a). An overview of serotonin neurochemistry and neuroanatomy. In M. SANDLER, A. COPPEN & S. HARNETT (Eds), 5-Hydroxytryptamine in psychiatry: a spectrum of ideas (pp. 23-36). London: Oxford University Press.
97. MURPHY, D. L. (1991b). The serotonin connection in OCD. Comments on 'Recent advances in obsessive-compulsive disorder'. Neuropsychopharmacology, 5, 11-12.
98. MURPHY, D. L. & PIGOTT, T. A. (1990). A comparative examination of a role for serotonin in obsessive compulsive disorder, panic disorder, and anxiety. Journal of Clinical Psychiatry, 51, 53-58.
99. MURPHY, D. L., MUELLER, E. A., HILL, J. L., TOLLIVER, T. J. & JACOBSEN, F. M. (1989). Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to health volunteers. Psychopharmacology, 98, 275-282.
100. MURPHY, D. L., GREENBERG, B., ALTEMUS, M., BENJAMIN, J., GRADY, T. & PIGOTT, T. (1996). The neuropharmacology and neurobiology of obsessive compulsive disorder: an update on the serotonin hypothesis. In H. G. M. WESTENBERG, D. L. MURPHY & J. A. DEN BOER (Eds), Advances in the neurobiology of anxiety disorders (pp. 279-297). New York: John Wiley & Sons.
101. NELSON, E. C., SHELINE, Y. I., BARDGETT, M. E., JACKSON, J. L. & CSERNANSKY, J. G. (1995). Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder. Psychiatry Research, 58, 117-125.
102. NEZEROGLU, F., ANEMONE, R. & YARYURA-TOBIAS, J. (1992). Onset of obsessive-compulsive disorder in pregnancy. American Journal of Psychiatry, 149, 947-950.
103. NOVELLI, R., NOBILE, M., DIAFERIA, G., SCIUTO, G. & CATALANO, M. (1994). A molecular investigation suggests no relationship between obsessive-compulsive disorder and the dopamine D2 receptor. Neuropsychobiology, 29, 61-63.
104. O'CONNOR, J. J. & KRUK, Z. L. (1994). Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro, Brain Research 640, 328-325.
105. PATIL, V. J. (1992). Development of transient obsessive-compulsive symptoms during the treatment with clozapine. American Journal of Psychiatry, 149, 272.
106. PATO, M. T., ZOHAR-KADOUCH, R., ZOHAR, J. & MURPHY, D. L. (1988). Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. American Journal of Psychiatry, 145, 1521-1525.
107. PAULS, D. L., ALSOBROOK, J. P., GOODMAN, W., RASMUSSEN, S. & LECKMAN, J. F. (1995). A family study of obsessive-compulsive disorder. American Journal of Psychiatry, 152, 76-84.
108. PERSE, T. L., GREIST, J. H., JEFFERSON, J. W., ROSENFELD, R. & DAR, R. (1987). Fluvoxamine treatment of obsessive-compulsive disorder. American Journal of Psychiatry, 144, 1543-1548.
109. PETERSON, B. S., LECKMAN, J. F., SCAHILL, L., NAFTOLIN, F., KEEFE, D., CHAREST, N. J. & COHEN, D. J. (1993). Steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome. Psychoneuroendocrinology, 17, 553-563.
110. PICCINELLI, M., PINI, S., BELLANTUONO, C. & WILKINSON, G. (1995). Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. British Journal of Psychiatry, 166, 424-443.
111. PIGOTT, T. A., PATO, M. T., BERNSTEIN, S. E., GROVER, G. N., HILL, J. L., TOLLIVER, T. J. & MURPHY, D. L. (1990). Controlled comparisons of clomipramine and fluoxetine in obsessive-compulsive disorder: behavioral and biological results. Archives of General Psychiatry, 47, 926-932.
112. PIGOTT, T. A., PATO, M. T., L'HEUREUX, F., HILL, J. L., GROVER, G. N., BERNSTEIN, S. E. & MURPHY, D. L. (1991). A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated OCD patients. Journal of Clinical Psychopharmacology, 11, 242-248.
113. PIGOTT, T. A., L'HEUREUX, F., BERNSTEIN, S. E., HILL, J. L. & MURPHY, D. L. (1992b). A controlled comparative therapeutic trial of clomipramine and m-chlorophenylpiperazine (m-CPP) in patients with obsessive-compulsive disorder. NCDEU Annual Meeting Abstracts, 26-29 May.
114. PIGOTT, T. A., HILL, J. L., GRADY, T. A., L'HEUREUX, F., BERNSTEIN, S., RUBENSTEIN, C. S. & MURPHY, D. L. (1993). A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effect of metergoline prior to IV m-CPP. Biological Psychiatry, 33, 3-14.
115. PINEYRO, G., BLIER, P., DENNIS, T. & DE MONTIGNY, C. (1994). Desensitization of the neuronal 5-HT carrier following its long-term blockade. Journal of Neuroscience, 14, 3036-3047.
116. RASMUSSEN, S. A. (1984). Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. American Journal of Psychiatry, 141, 1283-1285.
117. SANDLER, M., COPPEN, A. & HARNETT, S. (1991). 5-Hyroxytryptamine in psychiatry: a spectrum of ideas. London: Oxford University Press.
118. SAXENA, S., WANG, D., BYSTRITSKY, A. & BAXTER, L. R. J. (1996). Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. Journal of Clinical Psychiatry, 57, 303-306.
119. SCHWARTZ, P. J., WEHR, T. A., ROSENTHAL, N. E., BARTKO, J. J., OREN, D. A., LUETKE, C. & MURPHY, D. L. (1995). Serotonin and thermoregulation: physiologic and pharmacologic aspects of control revealed by intravenous m-CPP in normal human subjects. Neuropsychopharmacology, 13, 105-115.
120. SCHWARTZ, J. M., STOESSEL, P. W., BAXTER, L. R. J., MARTIN, K. M. & PHELPS, M. E. (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 53, 109-113.
121. SEIBYL, J. P., KRYSTAL, J. H., PRICE, L. H., WOODS, S. W., D'AMICO, C., HENINGER, G. R. & CHARNEY, D. S. (1991). Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Research, 38, 227-236.
122. STEIN, D. J., SPADACCINI, E. & HOLLANDER, E. (1995). Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. International Clinical Psychopharmacology, 10, 11-18.
123. SULTAN, S. & CHOUINARD, G. (1996). Atypical neuroleptics and obsessive-compulsive symptoms. American Psychiatric Association New Research Abstracts, 42
124. SWEDO, S. E., LEONARD, H. L., KRUESI, M. J. P., RETTEW, D. C., LISTWAK, S. J., BERRETTINI, W., STIPETIC, M., HAMBURGER, S., GOLD, P. W., POTTER, W. Z. & RAPOPORT, J. L. (1992). Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry, 49, 29-36.
125. SWEDO, S. E., LEONARD, H. L. & KIESSLING, L. S. (1994). Speculation on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics, 93, 323-326.
126. 2C serotonin receptors. Nature, 374, 542-546.
127. TOLLEFSON, G. D., RAMPEY, A. H., JR., POTVIN, J. H., JENIKE, M. A., RUSH, A. J., KOMINGUEZ, R. A., KORAN, L. M., SHEAR, M. K., GOODMAN, W. & GENDUSO, L. A. (1994). A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51, 559-567.
128. VALLEJO, J., OLIVARES, J., MARCOS, T., BULBENA, A. & MENCHON, J. M. (1992). Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. British Journal of Psychiatry, 161, 665-670.
129. WEISS, M., BAERG, E., WISEBORD, S. & TEMPLE, J. (1995). The influence of gonadal hormones on periodicity of obsessive-compulsive disorder. Canadian Journal of Psychiatry, 40, 205-207.
130. WHEADON, D. E., BUSHNELL, W. D. & STEINER, M. (1993). A fixed dose comparison on 20, 40, or 50 mg paroxetine to placebo in the treatment of obsessive compulsive disorder. Annual Meeting of American College of Neuropsychopharmacology, Honolulu, Hawaii.
131. WOOD, A., TOLLEFSON, G. D. & BIRKETT, M. (1993). Pharmacotherapy of obsessive compulsive disorder - experience with fluoxetine. International Clinical Psychopharmacology, 8, 301-306.
132. YARYURA-TOBIAS, J. A. & BHAGAVAN, H. N. (1977). L-Tryptophan in obsessive-compulsive disorders. American Journal of Psychiatry, 134, 1298-1299.
133. ZOHAR, J. & INSEL, T. R. (1987). Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biological Psychiatry, 22, 667-687.
134. ZOHAR, J. & JUDGE, R. (1997). Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. British Journal of Psychiatry (in press).
135. ZOHAR, J., MUELLER, E. A., INSEL, T. R., ZOHAR-KADOUCH, R. C. & MURPHY, D. L. (1987). Serotonergic responsivity in obsessive-compulsive disorder: comparison of patients and healthy controls. Archives of General Psychiatry, 44, 946.
136. ZOHAR, J., INSEL, T. R., ZOHAR-KADOUCH, R. C., HILL, J. L. & MURPHY, D. L. (1988). Serotonergic responsivity in obsessive-compulsive disorder. Archives of General Psychiatry, 45, 167-172.
137. ZOHAR, J., ZOHAR-KODOUCH, R. C. & KINDLER, S. (1992). Current concepts in the pharmacological treatment of obsessive-compulsive disorder. Drugs, 43, 210-218.